Xtl Biopharmaceuticals annual shares outstanding
2016
2017
2018
2019
2020
2021
2022
2024
Xtl Biopharmaceuticals Shares Outstanding History (XTLB)
Xtl Biopharmaceuticals reported 881.4M shares outstanding at the end of fiscal 2024.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 881.4M | 336.5M | +61.75% |
| 2022 | 2022-12-31 | 544.9M | 0 | 0.00% |
| 2021 | 2021-12-31 | 544.9M | 30.7M | +5.97% |
| 2020 | 2020-12-31 | 514.2M | 0 | 0.00% |
| 2019 | 2019-12-31 | 514.2M | 0 | 0.00% |
| 2018 | 2018-12-31 | 514.2M | 0 | 0.00% |
| 2017 | 2017-12-31 | 514.2M | 240.0M | +87.53% |
| 2016 | 2016-12-31 | 274.2M | — | — |
Xtl Biopharmaceuticals quarterly shares outstanding
Q4.16
Q4.17
Q4.18
Q4.19
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q4.24
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | 881.4M | 353.2M | +66.88% |
| Q4 2022 | 2022-12-31 | 544.9M | 30.7M | +5.97% |
| Q2 2022 | 2022-06-30 | 544.9M | 30.7M | +5.97% |
| Q4 2021 | 2021-12-31 | 544.9M | 30.7M | +5.97% |
| Q2 2021 | 2021-06-30 | 528.2M | 14.0M | +2.71% |
| Q4 2020 | 2020-12-31 | 514.2M | 240.0M | +87.53% |
| Q4 2019 | 2019-12-31 | 514.2M | — | — |
| Q4 2018 | 2018-12-31 | 514.2M | — | — |
| Q4 2017 | 2017-12-31 | 514.2M | — | — |
| Q4 2016 | 2016-12-31 | 274.2M | — | — |
Xtl Biopharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Xtl Biopharmaceuticals's shares outstanding moved from 514.2M to 881.4M, a change of 367.2M. The latest reported quarter, Q4 2024, shows 881.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals filings at SEC.gov ↗